Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to investigate the efficacy, safety, and tolerability of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.

"Funding Source - FDA OOPD"


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01868997
Study type Interventional
Source Horizon Pharma USA, Inc.
Contact
Status Completed
Phase Phase 2
Start date July 2013
Completion date February 22, 2017

See also
  Status Clinical Trial Phase
Completed NCT03948191 - 99Tc-MDP for Thyroid-Associated Ophthalmopathy Phase 4
Completed NCT02693808 - New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression N/A
Completed NCT01599273 - Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Phase 4
Completed NCT01579539 - The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Phase 3
Recruiting NCT02203682 - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy Phase 2
Terminated NCT00288522 - Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Phase 2
Recruiting NCT04936854 - Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease Phase 2
Completed NCT00595335 - Trial of Rituximab for Graves' Ophthalmopathy Phase 2/Phase 3